Tempest Therapeutics
TPST
90 hedge funds and large institutions have $237M invested in Tempest Therapeutics in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 17 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
6% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $11.2M
2% less funds holding
Funds holding: 92 → 90 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
68% less capital invested
Capital invested by funds: $745M → $237M (-$507M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$43.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.5M |
| 3 |
OH
Orbis Holdings
Hamilton,
Bermuda
|
+$16.8M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$7.27M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$6.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$15.6M |
| 2 |
GTP
Global Thematic Partners
New York
|
-$12.1M |
| 3 |
CCI
Columbus Circle Investors
|
-$8.06M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.94M |
| 5 |
DVC
Deer VII & Co
Larchmont,
New York
|
-$6.92M |
TPST Hedge Fund Activity: Q3 2015 in Review
90 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2015, worth a combined $237M — down 68% from $745M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TPST and 15 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 31 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $43.6M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $15.6M sold.
- 90 institutional investors held Tempest Therapeutics (TPST) as of Q3 2015, down from 92 in Q2 2015.
- Funds reported $237M of Tempest Therapeutics stock for Q3 2015, down 68% quarter-over-quarter.
- 15 funds opened new Tempest Therapeutics positions in Q3 2015 and 17 closed out, a net change of -2 holders.
- The largest Tempest Therapeutics buyer in Q3 2015 was ArrowMark Colorado Holdings, an estimated $43.6M added.
- The largest Tempest Therapeutics seller in Q3 2015 was Kingdon Capital Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q3 2015.